Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q3 2025 · 10-Q
Revenue$3.68M$3.68M−2.6% vs Q3 2024 Net Income-$29.78M-$29.78MN/M vs Q3 2024 EPS Diluted-$0.13-$0.13N/M vs Q3 2024 Operating Income-$3,786,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$3,628,000N/M Margins · derivedOperating margin-102.9%−1.2 pt vs Q3 2024
Net margin-809.0%−728.8 pt vs Q3 2024
ended Sep 30, 2025 · filed Nov 6, 2025 · 37 d after period end